The popular type 2 diabetes drug may cause profound changes in patients’ microbiomes.

A drug widely used to control glucose metabolism promotes neurogenesis, pointing to new directions for brain injury and disease therapeutics.

A roundup of recent research announced this week at the annual conference of the American Association for Cancer Research (AACR).